We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · May 25, 2021

Management of Rare RCC Subtypes—Chromophobe Renal Cell Carcinoma

Written by
Nazli Dizman MD


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • emine sevil bavbek

    Metastatectomy if feasible. Anti VEGF TKI if complete surgery not possible

  • Giuseppe Di Lucca

    1. Surgery and/or SBRT 2. Cabozantinib

  • Laszlo Torday

    Consider local ablative therapy first (metastasectomy or SBRT). If it is not feasible, I would do a biopsy and test the sample for PD-1 and cMET. Then, based on the result, you can choose sunitinib, cabozantinib, or pembrolizumab. And I would also review the circumstances of everolimus toxicity, focusing on dose reductions and supporting measures.

  • Jul 30, 2021

    Pending Moderator approval.

Further Reading